{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:31:03Z","timestamp":1773729063615,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Linkou Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CORPG5P0031"],"award-info":[{"award-number":["CORPG5P0031"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.amjmed.2025.12.011","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:29:34Z","timestamp":1765988974000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists"],"prefix":"10.1016","volume":"139","author":[{"given":"Jia-Jin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yu","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3782-8189","authenticated-orcid":false,"given":"Ching-Chung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2025.12.011_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4412","article-title":"Changes in the US burden of chronic kidney disease from 2002 to 2016: an analysis of the global burden of disease study","volume":"1","author":"Bowe","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0002","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0003","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0006","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0007","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-021-01258-x","article-title":"Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","volume":"20","author":"Lugner","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.14598","article-title":"The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study","volume":"24","author":"Ueda","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0009","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/M23-1874","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with stage 5 chronic kidney disease","volume":"177","author":"Yen","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0011","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0012","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0013","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0014","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hernan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0016","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0243","article-title":"Major adverse kidney events in pediatric continuous kidney replacement therapy","volume":"7","author":"Fuhrman","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0019","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.kint.2020.07.013","article-title":"International consensus definitions of clinical trial outcomes for kidney failure: 2020","volume":"98","author":"Levin","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0020","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0021","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0022","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s44200-021-00006-6","article-title":"Statistical inferences using effect sizes in human endothelial function research","volume":"27","author":"Cherubini","year":"2021","journal-title":"Artery Res"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0024","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"written on behalf of AMEB-DCTCG. Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112357","article-title":"Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes","volume":"226","author":"Yen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0027","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2022.06.027","article-title":"Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus","volume":"364","author":"Kim","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109231","article-title":"Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists","volume":"185","author":"Kobayashi","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101510","article-title":"Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis","volume":"50","author":"Lui","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0030","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00125-024-06251-z","article-title":"Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care","volume":"67","author":"Fadini","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0031","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12916-024-03483-z","article-title":"Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","volume":"22","author":"Sohn","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0032","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes","volume":"84","author":"Edmonston","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0033","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.ajkd.2025.05.005","article-title":"Kidney protective effects of glucagon-like Peptide-1 Receptor agonists Versus Sodium\/Glucose Cotransporter 2 inhibitors in persons with diabetes and CKD: implications for personalized medicine","volume":"86","author":"Taal","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0034","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","article-title":"Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus","volume":"16","author":"Zhang","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0036","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12933-023-01793-9","article-title":"The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","volume":"22","author":"Lin","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2018030296","article-title":"Sex-related disparities in CKD progression","volume":"30","author":"Ricardo","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2025.12.011_bib0038","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ajkd.2020.11.026","article-title":"CKD progression and mortality among men and women: a nationwide study in Sweden","volume":"78","author":"Swartling","year":"2021","journal-title":"Am J Kidney Dis"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325008393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325008393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:48:33Z","timestamp":1773722913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934325008393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0002934325008393"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.12.011","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}